Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Genetics Expects to Raise $12M in Public Offering of Stock

NEW YORK (GenomeWeb) – Cancer Genetics has priced a public offering of 3 million shares of its common stock at $4 per share, the company said today.

The firm is also offering five-year warrants to purchase 3 million shares of common stock at an exercise price of $5 per share. Cancer Genetics has granted the underwriters a 45-day option to purchase up to 450,000 additional shares of common stock and/or warrants.

In a document filed with the US Securities and Exchange Commission today, the Rutherford, New Jersey-based molecular diagnostics firm said it expects gross proceeds of $12 million and net proceeds of $10.5 million after expenses from the offering.

Joseph Gunnar & Co. and Feltl and Company are joint book runners for the offering while Axiom Capital Management is co-manager.

The offering is expected to close on or around Nov. 12.

Shares of Cancer Genetics were down 15 percent this morning on the Nasdaq at $3.90.

Last month, Cancer Genetics bought the assets of Response Genetics — which had filed for Chapter 11 bankruptcy — for $14 million.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.